Cargando…
Suppressing LncRNA HOXA-AS3 by CRISPR-dCas9 inhibits pancreatic cancer development
The lncRNA HOXA-AS3 has been reported as a potential oncogene in tumors. Nevertheless, the molecular mechanism of HOXA-AS3 in pancreatic cancer (PC) progression remains unknown. We performed quantitative real-time (qRT) PCR assay to detect the expression levels of HOXA-AS3, miR-29c in PC specimens....
Autores principales: | Zhang, Xiaoli, Zhu, Hongbo, Qu, Xiaoguang, Yu, Ziying, Zhang, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489150/ https://www.ncbi.nlm.nih.gov/pubmed/34659534 http://dx.doi.org/10.7150/jca.62631 |
Ejemplares similares
-
Knockdown of LncRNA PANDAR by CRISPR-dCas9 Decreases Proliferation and Increases Apoptosis in Oral Squamous Cell Carcinoma
por: Jia, Tingting, et al.
Publicado: (2021) -
Transcriptional Inhibition of lncRNA gadd7 by CRISPR/dCas9-KRAB Protects Spermatocyte Viability
por: Zhao, Jun, et al.
Publicado: (2021) -
An Improved CRISPR/dCas9 Interference Tool for Neuronal Gene Suppression
por: Duke, Corey G., et al.
Publicado: (2020) -
Detection of CRISPR-dCas9 on DNA with Solid-State
Nanopores
por: Yang, Wayne, et al.
Publicado: (2018) -
Multistage Delivery Nanoparticle Facilitates Efficient CRISPR/dCas9 Activation and Tumor Growth Suppression In Vivo
por: Liu, Qi, et al.
Publicado: (2018)